期刊文献+

卡培他滨联合草酸铂化疗结直肠癌的疗效探讨

原文传递
导出
摘要 目的探讨卡培他滨(商品名:希罗达)联合草酸铂(L-OHP)化疗结直肠癌的近期疗效及毒副反应。方法34例晚期结直肠癌患者,给予卡培他滨2000mg·m^-2·d^-1,分2次口服,连服14d。L-OHP 100mg·m^-2·d^-1,持续2-3h静脉滴注,第1天应用。21d为1个周期,至少用2个周期评价疗效,每周期观察毒副反应。结果34例患者中可评价疗效者31例,CR2例,PR14例,sD10例,PD5例,总有效(CR+PR)率51.6%,获益率85.2%。Ⅲ、Ⅳ度毒副反应为:腹泻2例,感觉神经毒性反应2例,手足综合征1例。Ⅰ、Ⅱ度毒副反应为:腹泻11例,感觉神经毒性反应18例,手足综合征8例,皮肤色素沉着10例,骨髓抑制5例。结论卡培他滨联合L—OHP治疗晚期结直肠癌疗效可靠,毒副反应可以耐受。
作者 田秀岭
出处 《肿瘤研究与临床》 CAS 2007年第1期50-51,共2页 Cancer Research and Clinic
  • 相关文献

参考文献9

  • 1Mettem J, Koommagi R, Volm M. Biological characterization ofsubgrorps of squamous cell lung carcinomas [J]. Clin Cancer Res,1999, 5(6): 1459.
  • 2Koizumi W, Salgenji K, Nakarnaru N, et al. Prediction of responseto 5-deoxy-5-fluorouridine (5-DFUR) in patients with inoperableadvance gastric cancer by immunostaining of thymidine phosphory-lase/plateletdefived endothelial cell growth factor [J]. Oncology,1999, 56(3): 215.
  • 3管忠震,刘冬耕,郁宝铭,吴唯勤,时德,赵瑜,魏于全,邹立群,伍晓汀,庄文,冯奉仪,张频,于世英,熊慧华,付强,郑树,黄建瑾,伍钢,杨传永,孙圣荣,阮庆兰.希罗达一线治疗晚期或复发性结直肠癌[J].中华肿瘤杂志,2004,26(2):119-121. 被引量:72
  • 4Bleiberg H. Oxalliplatin(L-OHP):a new reality in colorectal cancer[J]. Br J Cancer, 1998, 77(suppl 4): 1-3.
  • 5Becouarn Y, Rougier P. Clinical efficacy of oxaliplatin monotherapy:phase trials in advancd colorectal cancer[J]. Semin oncol, 1998,25(2 suppl 5): 23-31.
  • 6Jin M L, Chen Q, Cheng F Q, et al. Oxaliplatin(OXA) in combination with LVSFU2 in chinese patients with advanced gastric cancer(AGC) [J]. Proc ASCO, 2002. 21: 558-560.
  • 7Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyfimidine carbamate, capecitabine,which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver andcancer tissue[J]. Eur J Cancer, 1998, 34(8): 1274-1281.
  • 8Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients[J]. Cancer chemother Pharmacol, 2000, 45(4): 291- 297.
  • 9肖毅军,陈小兵,罗素霞,马杰.术前希罗达化疗对大肠癌组织TP/PD-ECGF表达和血管生成的影响[J].中国肿瘤临床与康复,2005,12(2):97-99. 被引量:7

二级参考文献7

  • 1Mattern J,Koommagi R,Volm M. Biological characterization of subgroups of squamous cell lung carcinomas[J].Clin Cancer Res,1999,5(6): 1459.
  • 2Miwa M,Ura M,Nishida M,et al. Design of novel oral fluoropyrimidine carbamate capecitabine,which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue[J].Eur J Cancer,1998,34(8):1274.
  • 3Koizumi W,Salgenji K,Nakamaru N,et al. Prediction of response to 5-deoxy-5-fluorouridine (5-DFUR) in patients with inoperable advance gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor[J]. Oncology,1999,56(3):215.
  • 4Okamoto E,Osaki M,Kase S,et al. Thymidine phosphorylase expression causes both the increase of intratumoral microvessel and decrease of apoptosis in human esophageal carcinomas[J].Pathology,2001,51(3):158.
  • 5Semiglazova TU,Gershanovlch ML. Xeloda(capecetabine) in the treatment of disseminated breast cancer after failure with anthracyclines and taxanes[J].Voprosy Oncology,2001,47(3):298.
  • 6Johannes Schüller,Jim Cassidy,Etienne Dumont,Brigitte Roos,Sarah Durston,Ludger Banken,Masahiro Utoh,Kazushige Mori,Erhard Weidekamm,Bruno Reigner. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients[J] 2000,Cancer Chemotherapy and Pharmacology(4):291~297
  • 7王宝成,毕经旺,李志.靶向化疗——氟化嘧啶类药物的研究进展[J].国外医学(肿瘤学分册),2001,28(6):447-451. 被引量:73

共引文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部